Riyaz U Saif1, Hilal Ahmad Dar2, Sozia Mohammad Sofi1, Mushtaq Saif Andrabi3, Gul Javid1, Showkat Ali Zargar1. 1. Department of Gastroenterology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, 190 011, India. 2. Department of Gastroenterology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, 190 011, India. drhilaldar@gmail.com. 3. Government Medical College, Srinagar, 190 010, India.
Abstract
BACKGROUND:Hepatorenal syndrome (HRS) occurs in decompensated liver disease and carries high mortality. Vasoconstrictors are the drug of choice. Terlipressin is widely used and is expensive. In this study, we compared noradrenaline and terlipressin in the management of type 1 HRS. METHODS:Sixty consecutive patients with type 1 HRS were managed with noradrenaline (Group A, n = 30) or terlipressin (Group B, n = 30) with albumin in a randomized controlled trial at a tertiary center. RESULTS: Reversal of type 1 HRS was achieved in 16 (53%) patients in group A and 17 (57%) in group B. There was statistically insignificant difference between the two groups in decreasing serum creatinine and increasing urine output (p > 0.05). On univariate analysis, Child-Turcotte-Pugh (CTP) score, serum sodium, serum urea, serum albumin, prothrombin time, International normalized ratio (INR), serum alanine aminotransferase (ALT), ascitic fluid protein, and history of bleeding were associated with response to treatment (noradrenaline/terlipressin). However, on multivariate analysis, only baseline CTP score, serum urea, serum albumin, and prothrombin time were independent predictors of response. All patients who responded were discharged alive with no mortality within 30 days. CONCLUSIONS: There is no difference in outcome of patients with type 1 HRS treated with noradrenaline or terlipressin. Thus, noradrenaline, which is cheaper, can be used instead of terlipressin (Clinical Trials Registry-India [CTRI] No. CTRI/2011/09/002032).
RCT Entities:
BACKGROUND:Hepatorenal syndrome (HRS) occurs in decompensated liver disease and carries high mortality. Vasoconstrictors are the drug of choice. Terlipressin is widely used and is expensive. In this study, we compared noradrenaline and terlipressin in the management of type 1 HRS. METHODS: Sixty consecutive patients with type 1 HRS were managed with noradrenaline (Group A, n = 30) or terlipressin (Group B, n = 30) with albumin in a randomized controlled trial at a tertiary center. RESULTS: Reversal of type 1 HRS was achieved in 16 (53%) patients in group A and 17 (57%) in group B. There was statistically insignificant difference between the two groups in decreasing serum creatinine and increasing urine output (p > 0.05). On univariate analysis, Child-Turcotte-Pugh (CTP) score, serum sodium, serum urea, serum albumin, prothrombin time, International normalized ratio (INR), serum alanine aminotransferase (ALT), ascitic fluid protein, and history of bleeding were associated with response to treatment (noradrenaline/terlipressin). However, on multivariate analysis, only baseline CTP score, serum urea, serum albumin, and prothrombin time were independent predictors of response. All patients who responded were discharged alive with no mortality within 30 days. CONCLUSIONS: There is no difference in outcome of patients with type 1 HRS treated with noradrenaline or terlipressin. Thus, noradrenaline, which is cheaper, can be used instead of terlipressin (Clinical Trials Registry-India [CTRI] No. CTRI/2011/09/002032).
Entities:
Keywords:
CTP score; Cirrhosis; International normalized ratio; Model for end-stage liver disease score
Authors: Paolo Angeli; Pere Ginès; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao Journal: J Hepatol Date: 2015-01-28 Impact factor: 25.083
Authors: A Maroto; P Ginès; V Arroyo; A Ginès; J Saló; J Clària; W Jiménez; C Bru; F Rivera; J Rodés Journal: Hepatology Date: 1993-05 Impact factor: 17.425
Authors: Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber Journal: Gastroenterology Date: 2008-02-13 Impact factor: 22.682
Authors: Antonio Paulo Nassar Junior; Alberto Queiroz Farias; Luiz Augusto Carneiro D' Albuquerque; Flair José Carrilho; Luiz Marcelo Sá Malbouisson Journal: PLoS One Date: 2014-09-09 Impact factor: 3.240
Authors: Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Eng-Loon Tng; Mario Csenar; Neil Hawkins; Chavdar S Pavlov; Brian R Davidson; Douglas Thorburn; Maxine Cowlin; Elisabeth Jane Milne; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2019-09-12
Authors: Jingqiao Zhang; Jie Liu; Yunhai Wu; Fernando Gomes Romeiro; Giovanni Battista Levi Sandri; Xinmiao Zhou; Miaomiao Li; Xingshun Qi Journal: Ann Transl Med Date: 2020-03